Vogt Koyanagi Harada Disease Clinical Trial
Official title:
Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study
This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | February 2025 |
Est. primary completion date | May 18, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 70 Years |
Eligibility | Inclusion criteria: - acute Vogt-Koyanagi-Harada disease Exclusion criteria: - non collaborative patient - minimum one-year follow-up |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de Sao Paulo | São Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo |
Brazil,
da Silva FT, Damico FM, Marin ML, Goldberg AC, Hirata CE, Takiuti PH, Olivalves E, Yamamoto JH. Revised diagnostic criteria for vogt-koyanagi-harada disease: considerations on the different disease categories. Am J Ophthalmol. 2009 Feb;147(2):339-345.e5. — View Citation
da Silva FT, Hirata CE, Olivalves E, Oyamada MK, Yamamoto JH. Fundus-based and electroretinographic strategies for stratification of late-stage Vogt-Koyanagi-Harada disease patients. Am J Ophthalmol. 2009 Dec;148(6):939-45.e3. doi: 10.1016/j.ajo.2009.06.0 — View Citation
da Silva FT, Hirata CE, Sakata VM, Olivalves E, Preti R, Pimentel SL, Gomes A, Takahashi WY, Costa RA, Yamamoto JH. Indocyanine green angiography findings in patients with long-standing Vogt-Koyanagi-Harada disease: a cross-sectional study. BMC Ophthalmol — View Citation
da Silva FT, Sakata VM, Nakashima A, Hirata CE, Olivalves E, Takahashi WY, Costa RA, Yamamoto JH. Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2013 Jan;97(1):70-4. doi: 10.1136/bjophth — View Citation
Damico FM, Bezerra FT, Silva GC, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol. 2009 May-Jun;72(3):413-20. doi: 10.1590/s0004-27492009000300028. — View Citation
Herbort CP Jr, Abu El Asrar AM, Yamamoto JH, Pavesio CE, Gupta V, Khairallah M, Tugal-Tutkun I, Soheilian M, Takeuchi M, Papadia M. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol. 20 — View Citation
Lavezzo MM, Sakata VM, Morita C, Rodriguez EE, Abdallah SF, da Silva FT, Hirata CE, Yamamoto JH. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016 Mar 24;11:29. doi: 10.1186/s130 — View Citation
Morita C, Sakata VM, Rodriguez EE, Abdallah SF, Lavezzo MM, da Silva FT, Machado CG, Oyamada MK, Hirata CE, Yamamoto JH. Fundus autofluorescence as a marker of disease severity in Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2016 Dec;94(8):e820-e821. do — View Citation
Sakata VM, da Silva FT, Hirata CE, de Carvalho JF, Yamamoto JH. Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev. 2014 Apr-May;13(4-5):550-5. doi: 10.1016/j.autrev.2014.01.023. Epub 2014 Jan 15. — View Citation
Sakata VM, da Silva FT, Hirata CE, Marin ML, Rodrigues H, Kalil J, Costa RA, Yamamoto JH. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2015 M — View Citation
Sakata VM, da Silva FT, Hirata CE, Takahashi WY, Costa RA, Yamamoto JH. Choroidal bulging in patients with Vogt-Koyanagi-Harada disease in the non-acute uveitic stage. J Ophthalmic Inflamm Infect. 2014 Feb 18;4(1):6. doi: 10.1186/1869-5760-4-6. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | scotopic electroretinogram results | scotopic results variation between 12 months and 6 months | 6 month; 12 month | |
Secondary | presence of optic disc hyperfluorescence detected on fluorescein angiography | presence of optic disc hyperfluorescence and variation in intensity in consecutive examinations | between 6 and 12 months from disease onset. | |
Secondary | presence of perivascular leakage on fluorescein angiography | presence of perivascular leakage and variation in extension and intensity in consecutive examinations | between 6 and 12 months from disease onset. | |
Secondary | presence of dark dots on indocyanine green angiography | dark dots score and its fluctuation | between 6 and 12 months from disease onset. | |
Secondary | subfoveal choroidal thickness on enhanced depth imaging optical coherence tomography | subfoveal choroidal thickness and its variation | between 6 and 12 months from disease onset. | |
Secondary | presence of cells in anterior chamber graduated according to SUN criteria | presence of cells in anterior chamber and its variation | between 6 and 12 months from disease onset. | |
Secondary | presence of choroidal neovascular membrane on OCT and/or FA | choroidal neovascular membrane | between 6 and 12 months from disease onset. | |
Secondary | presence of macular edema on OCT and/or FA | macular edema detected clinically, angiographically and/or by optical coherence tomography | between 6 and 12 months from disease onset. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05496530 -
Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)
|
N/A | |
Withdrawn |
NCT00407121 -
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
|
Phase 3 | |
Completed |
NCT05031143 -
Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment
|
Phase 2/Phase 3 |